Zimmer Biomet Holdings, Inc. ZBH
This picture changes. Follow Zimmer Biomet Holdings, Inc. free — email when the signal or risk changes + a Sunday weekly brief.
Follow Zimmer Biomet Holdings, Inc. freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 1 Aug 2026
Latest news check: 6 Aug 2026
General analysis — not personal advice.
HOLD
7/10
Confidence
Existing position can be maintained pending the Q2 report for clearer direction.
Stable profitability, strong cash flows and raised guidance after the Q2 report support the ongoing HOLD signal.
Market sentiment
8/10
↑
Trend: Improving
The market reacts positively to the earnings beat and raised guidance, with analyst consensus strengthening toward buy.
Price context
The stock closed at 98.16 USD after the report, roughly 11% below its 52-week high, indicating some remaining upside despite the pop.
Risk assessment
7/10
Dilution:
Low
Focus on buybacks rather than new share issuance
Jurisdiction:
Low
Primary operations in the US and Europe
Execution:
Medium
Ongoing sales force restructuring and integration work
Recent changes
- ▲ Sentiment score rose following the report release and raised guidance which strengthened analyst consensus.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (2) — follow the company freeAbout the company
Zimmer Biomet is a leading medical technology company that develops and sells orthopedic implants for knees, hips and extremities as well as robot-assisted surgical solutions such as the ROSA platform. The company holds a strong market position in orthopedics with recurring revenues from implants and surgical tools.
Sector:
Orthopedic implants and robotic surgery
Type:
Industrial
Next report
5 Nov 2026
Q3
Catalysts
Nov 2026
Q3 report
High
Q4 2026
Monogram FDA approval
Medium
Horizon:
Bull case
Raised full-year guidance and strong growth in the technology and robotics segments provide support for the stock.
Bear case
High leverage and weaker performance in certain international markets limit upside.
Sensitivity analysis
| Factor | If it weakens | If it strengthens |
|---|---|---|
| ROSA robotics adoption | Slower installations → lower growth in the surgical segment and weaker organic development. | Faster adoption → higher robotics revenues and improved competitive position versus Stryker and J&J. |
| Monogram robotic platform | Regulatory approval delays → postponed commercialization and reduced growth contribution. | Early clearances → accelerated market penetration and improved product mix. |
We monitor these factors. Follow the company to get email when any of them hit.
Signal rationale (informational)
Stable profitability, strong cash flows and raised guidance after the Q2 report support the ongoing HOLD signal.
Recent news
- Q2 2026 results showed revenue of 2.177 billion USD with 4.0% organic growth. The company beat adjusted EPS estimates at 2.07 USD and raised full-year guidance for both revenue and earnings. The stock rose over 2.5% on the report day.
Key figures
Revenue
Q2 2026
USD 2.2B
Revenue TTM
TTM
USD 8.4B
EBITDA
Q2 2025
USD 500M
Net income
Q2 2026
USD 198M
Cash
Q1 2026
USD 424M
Total debt
Q1 2026
USD 7.5B
Shares outstanding
Q1 2026
193M
EPS
Q2 2026
USD 1.03
Price & valuation
Last close
USD 97.23
Market Cap
USD 18.8B
1 week
-0.9 %
3 months
+17.5 %
12 months
-4.5 %
From 52w high
-9.7 %
From 52w low
+22.2 %
Exchange
NYSE
Type
Industrials
Sector
Orthopedic implants and robotic surgery
This picture changes. Follow Zimmer Biomet Holdings, Inc. free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.